+1-206-701-6702
+44-020-8133-4027
+81-50-5539-1737
+91-848-285-0837
Allogeneic human chondrocyte is an emerging therapy, which can be used for cartilage repair and other indications. Currently, very few market players are developing these therapies, wherein the studies are in clinical trial phase and are expected to soon receive approval from the regulatory agencies. For instance, Invossa, from Kolon TissueGene, Inc., is expected to be the world’s first cell-and-gene therapy for osteoarthritis. This therapy is going to be a cartilage cells extracted from human cartilage (first fluid of HC) and transformed cells with TGF-β1 (second fluid of TC) by the ratio of 3:1. The product is currently in phase 3 clinical trial phase. This is expected to create lucrative opportunity for players to develop such therapies in the near future.
The Europe allogeneic human chondrocyte market is expected to be valued at US$ 3,440.5 million in 2027 and is expected to exhibit a CAGR of 10.2% during the forecast period (2026-2027).
Figure 1. Europe Allogeneic Human Chondrocyte Market Share (%) in Terms of Value, By Country, 2027
Rising incidence of falls and knee cartilage injuries is expected to propel the market growth during the forecast period
Increasing cases of falls and knee cartilage injuries is a major factor that is expected to propel growth of the Europe allogeneic human chondrocyte market over the forecast period. According to the article published in the British Medical Journal (BMJ Journal) February 2020, the incidence of falls in European countries were as follows in 2017: in the Western European region, 13,840 per 100,000 population seek medical treatment for fall related injury, of which 7,594/100,000 are from Greece and 19,796 are from Norway.
Figure 2. Europe Allogeneic Human Chondrocyte Market Share (%), by Application, 2027
Increasing prevalence of musculoskeletal system disorders is expected to propel the market growth over the forecast period
Increasing cases of musculoskeletal system disorders is expected to drive the market growth during the forecast period. According to the State of Musculoskeletal Health, 2019 report by the Versus Arthritis, the prevalence of musculoskeletal conditions in the U.K. in 2017, was as follows:
| Country | Prevalence of Musculoskeletal Conditions |
|---|---|
| England | 15,899,000 |
| Scotland | 1,525,000 |
| Northern Ireland | 487,200 |
| Wales | 887,000 |
Europe Allogeneic Human Chondrocyte Market - Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic is affecting clinical trials, drastically. According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they have stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2020: | |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 10.2% | 2027 Value Projection: | US$ 3,440.5 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Kolon TissueGene, Inc., and ISTO Technologies Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Furthermore, ongoing clinical trials are being conducted by healthcare facilities and researchers using the following safety measures:
Europe Allogeneic Human Chondrocyte Market Restraints:
As the research for human allogeneic chondrocyte is ongoing and products are majorly in the development phase, the research cost and procedures are considerably high and tedious, which can affect the development of such products and is expected to hinder growth of the market.
Moreover, the disadvantages of allogeneic transplantation as compared to autologous transplantation is expected to limit the adoption of allogeneic transplantation, thereby hindering the Europe allogeneic human chondrocyte market growth.
Key Players
Major players operating in the Europe allogeneic human chondrocyte market include Kolon TissueGene, Inc. and ISTO Technologies Inc.
Allogeneic human chondrocyte cell therapy is anticipated to be a good alternative to autologous chondrocyte implantation in the near future. Increasing product approvals by regulatory authorities is expected to fuel the market growth over the forecast period. For instance, in July 2017, Kolon TissueGene, Inc. received the South Korea Ministry of Food & Drug Safety (MFDS) for Invossa-K Inj. The product is currently available in the South Korean market and is marketed by Mundipharma and Kolon Pharmaceuticals.
Market Dynamics
Most of the pharmaceutical manufacturers operating in the Europe allogeneic human chondrocyte market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and agreements to strengthen their market presence and expand its geographical footprint. In June, Kolon TissueGene, Inc., a manufacturer and developer of advanced cell and gene therapies, announced the extension of license agreement with Kolon Life Science, Inc., for the sales of Invossa-K Inj, a cell and gene therapy for knee osteoarthritis. The agreement is expected to expand the geographical footprint of Kolon Life Science, Inc. in the Middle East region with the grant of license for Saudi Arabia and United Arab Emirates (UAE) by the year 2024.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
